Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein

British Journal of Clinical Pharmacology

Volumn 59, Issue 4, 2005, Pages 440-446

  Pinto, A G ^a   Horlander, J ^a   Chalasani, N ^a   Hamman, M ^a   Asghar, A ^a   Kolwankar, D ^a   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A; Diltiazem; Intestinal biopsy; Irreversible inhibition; Midazolam

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DILTIAZEM; MESSENGER RNA; MIDAZOLAM; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOBLOTTING; INTESTINE BIOPSY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; DUODENUM; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 17144413347     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02343.x     Document Type: Article

References (30)

1. Thummel KE, Wilkinson CR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-430.
2. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Castroenterol Clin North Am 1992; 21: 511-26.
3. Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29: 387-454.
4. Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 1985; 34: 2549-53.
5. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996; 59: 369-75.
6. Thomas AR, Chan LN, Bauman JL, Olopade CO. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy 1998; 18: 381-5.
7. Ahonen J, Olkkola KT, Salmenpera M, Hynynen M, Neuvonen PJ. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 1996; 85: 1246-52.
8. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-74.
9. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369-77.
10. Yeung PK, Buckley SJ, Hung OR, Pollak PT, Barclay KD, Feng JD, et al. Steady-state plasma concentrations of diltiazem and its metabolites in patients and healthy subjects. Ther Drug Monit 1996; 18: 40-5.
11. Sutton D, Butler AM, Nadin L, Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 1997; 282: 294-300.
12. Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000; 28: 1031-7.
13. Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochromes P450, 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 1995, 49: 591-602.
14. Jones DR, Corski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999; 290: 1116-25.
15. Lowry OH, Rosenbrough NH, Farr AL, Randall FJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
16. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281: 1349-55.
17. Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, et al. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 2002; 53: 67-74.
18. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22: 947-55.
19. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999; 66: 33-9.
20. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64: 133-43.
21. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298-305.
22. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8.
23. Abernethy DR, Montamat SC. Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. Am J Cardiol 1987; 60: 1161-201.
24. Watkins PB, Wrighton SA, Maurel P, Schuetz EC, Mendez-Picon C, Parker GA, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 1985; 82: 6310-4.
25. Larrey D, Funck-Brentano C, Breil P, Vitaux J, Theodore C, Babany G, et al. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983; 32: 1063-8.
26. Hosteller KA, Wrighton SA, Molowa DT, Thomas PE, Levin W, Guzelian PS. Conduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Mol Pharmacol 1989; 35: 279-85.
27. Wrighton SA, Campanile C, Thomas PE, Maines SL, Watkins PB, Parker G, et al. Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. Mol Pharmacol 1986; 29: 405-10.
28. Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, Letteron P, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989; 250: 746-51.
29. Lown KS, Bailey DC, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997, 99, 2545-53.
30. Pichard L, Fabre I, Fabre G, Domergue J, Saint AB, Mourad G, et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606.